Barclays analyst Peter Lawson maintained a Buy rating on Replimune Group (REPL – Research Report) today and set a price target of $17.00. The ...

Equities researchers at Wedbush decreased their FY2025 earnings estimates for shares of Replimune Group in a research report ...

Research analysts at Leerink Partnrs lowered their FY2025 earnings estimates for Replimune Group in a report released on Wednesday, February 12th. Leerink Partnrs analyst J. Chang now forecasts that ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...